BDP9066 is a potent and selective myotonic dystrophy-related Cdc42-binding kinase MRCK inhibitor with an IC 50 of 64 nM for MRCKβ in SCC12 cells, K i values of 0.0136 nM and 0.0233 nM for MRCKα/β in house determinations, respectively. BDP9066 has therapeutic effect on skin cancer by reducing substrate phosphorylation.In VitroBDP9066 shows antiproliferative effects with greatest activity in hematologic cancer cells. BDP9066 inhibits MLC phosphorylation and blocks SCC12 squamous cell carcinoma motility and invasion. MCE has not independently confirmed the accuracy of these methods. They are for reference only.In VivoBDP9066 topical application significantly decreases phosphorylated MRCKα S1003 staining and tumor volumes . MCE has not independently confirmed the accuracy of these methods. They are for reference only.Form:SolidIC50& Target:IC50: 64 nM (MRCKβ in SCC12 cells), Ki: 0.0136 nM/0.0233 nM (MRCKα/β). Specification: 0.98 Molecular Formula: C20H24N6 Molecular Weight: 348.44 PubChem CID: 132275018
- UPC:
- 12352005
- Condition:
- New
- Availability:
- 8-12 weeks
- Weight:
- 1.06 Ounces
- HazmatClass:
- No
- WeightUOM:
- LB
- MPN:
- B651933-25mg
- CAS:
- 2226507-04-4
- Product Size:
- 25mg
